Cardiovasc

Assessment of Proarrhythmic Adverse Effects during Drug Development: Current Status and Challenges Ahead

  • Chair(s):

    Jules Hancox,
    Professor of Cardiac Electrophysiology,School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom

    Paul Volders,
    Cardiologist and Principal Investigator,Department of Cardiology, CARIM, Maastricht University Medical Center, Maastricht, The Netherlands

  • Session description:

    Mechanisms of drug-induced arrhythmia: implications for cardiac safety evaluation of drugs in development
    Professor Jules Hancox
    Professor of Cardiac Electrophysiology, School of Physiology, Pharmacology and Neuroscience, University of Bristol, United Kingdom

    Current approaches to the assessment of proarrhythmic potential of drugs and surrogate parameters of drug-induced arrhythmia
    Professor Paul Volders
    Cardiologist and Principal Investigator, Department of Cardiology, CARIM, Maastricht University Medical Center, Maastricht, The Netherlands

    Oral communication speaker - to be confirmed in 2022. Evaluation of the hidden cardiotoxic effects of COX2 inhibitors
    Dr Gabor Brenner
    Department of Pharmacology and Pharmacotherapy, Semmelweis University Hungary, Budapest,
    Hungary

    Transgenic Rabbit Models for Proarrhythmia Prediction
    Professor Katja Odening
    Department of Cardiology and Angiology I, Heart Center, University of Freiburg Germany, Freiburg,
    Germany
    Department of Physiology, University of Bern, Bern, Switzerland

  • 00

    days

  • 00

    hours

  • 00

    minutes

  • 00

    seconds

Date

06 Jul 2023

Time

9:45 am - 12:10 pm

Speakers

Leave A Comment

Go to Top